New combo therapy aims to shrink esophageal tumors before surgery
NCT ID NCT06869213
First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 32 times
Summary
This study is testing whether adding the drug adebrelimab to standard chemotherapy before surgery, and continuing it alone after surgery, can help people with a certain type of esophageal cancer. The goal is to see if this approach can eliminate or shrink the tumor more effectively. About 30 adults with locally advanced but removable esophageal cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER (ESC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.